Aragen Operationalise $30 Million Bangalore Biologics Facility

• Aragen has operationalised the first phase of its biologics manufacturing facility in Bangalore, India

• The facility represents a $30 million investment and has completed its first small-scale manufacturing project for a US-based organisation, producing a novel anticancer monoclonal antibody (mAb).

Aragen, a Contract Research Development and Manufacturing Organisation (CRDMO) specialising in small molecules and biologics, has announced the operationalisation of the first phase of its biologics manufacturing facility in Bangalore, India.

The $30 million facility has completed its inaugural small-scale manufacturing project for a US-based organisation for an anticancer monoclonal antibody (mAb). The non-GMP facility can undertake batch sizes up to 50 Litres and includes process development and analytical labs.

Manni Kantipudi, CEO of Aragen Life Sciences and Director of Aragen Biologics Pvt Ltd, commented, “We are happy to announce the commissioning of the first phase of our biologics manufacturing facility at Bangalore, India, as per schedule and the successful completion of the first project at this facility. This brings us one step closer to offering full-scale Gene-to-GMP solutions to our customers.”

Aragen’s biologics manufacturing facility in Bangalore is equipped to handle batch sizes up to 50 litres and includes state-of-the-art process development and analytical labs. The facility’s expansion, expected to be fully operational by the end of the calendar year, will enable internal tech transfer from Aragen’s R&D labs in California to the manufacturing site in India, facilitating end-to-end integrated service offerings.

The Bangalore facility complements Aragen’s existing services, including discovery and development research from its R&D labs in California, USA. These services encompass cell line development, upstream and downstream development, protein science, and antibody discovery. With advanced single-use bioreactors ranging from 50 to 2000 litres, the facility can accommodate diverse production needs, including mAbs, therapeutic proteins, and fusion proteins.